ECOG Trial Outcomes in Smoldering Myeloma

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers discusses the outcomes from the ECOD trial in smoldering multiple myeloma (MM).